SCHEMBL3916604

SCHEMBL3916604

COC(=O)N(C)c1ccc(OCC(=O)OCC[Si](C)(C)C)cc1OCc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
CYP19A1 P11511 3/20 0.39
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
MAPK1 P28482 1/20 0.38
LTA4H P09960 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MTNR1A P48039 1/20 0.37
MTNR1B P49286 1/20 0.37
EPOR P19235 1/20 0.36
HCRTR2 O43614 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3922237 0.83 ALDH1A1 (0.46) KDM4ELMNAPOLBMEN1KMT2A
SCHEMBL3927338 0.81 KEAP1 (0.49) KEAP1NFE2L2
SCHEMBL3916606 0.80 KDM4E (0.43) KDM4ELMNAPOLBMEN1KMT2A
SCHEMBL4309433 0.78 ALDH1A1 (0.41) KDM4ELMNAPOLBMEN1KMT2A
SCHEMBL3919065 0.77 KEAP1 (0.43) KEAP1NFE2L2
SCHEMBL27738006 0.76 CYP19A1 (0.49) LMNAMEN1KMT2ACYP19A1KEAP1
SCHEMBL3917049 0.71 PTPN1 (0.39) KDM4ELMNAPOLBMEN1KMT2A
SCHEMBL9811660 0.69 HPGD (0.57) KDM4ELMNAPOLBMEN1KMT2A
SCHEMBL2465531 0.66 SMN1; SMN2 (0.44) LMNAALDH1A1SMN1; SMN2MAPK1L3MBTL1
SCHEMBL12056123 0.66 ALDH1A1 (0.45) KDM4EPOLBALDH1A1MAPTKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084448-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 US disclosed
US-20090181928-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-07-16 US disclosed
EP-2038267-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE Novartis AG (CH) 2009-03-25 EP disclosed
WO-2007115058-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE NOVARTIS AG (CH) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181928-A1 ORGANIC COMPOUNDS PTPRS, PTPRO, PTPRC KDM4E 2248/4885LMNA 4825/4885POLB 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.